AmerisourceBergen

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Retrieved on: 
Mardi, mai 28, 2024
Patient, Outlook, AMD, Literature, Commission, Marketing, Ophthalmology, European Medicines Agency, Calendar, Therapy, Drug development, Senior, Civil service commission, European Commission, Research, Bevacizumab, Pharmacovigilance, AmerisourceBergen, Pharmaceutical industry

LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU.

Key Points: 
  • LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU.
  • This decision applies automatically in all 27 EU Member States and, within 30 days, also to Iceland, Norway and Liechtenstein.
  • Additionally, the Marketing Authorization grants Outlook an initial ten years of market exclusivity in the EU for LYTENAVA™ (bevacizumab gamma).
  • The EU represents the second largest wet AMD market in the world, and we look forward to continuing our efforts to bring to the EU market the first and only on-label, ophthalmic bevacizumab for the treatment of wet AMD.

AmerisourceBergen Specialty Group Provides Substitute Notice of Data Incident to Affected Individuals

Retrieved on: 
Vendredi, mai 24, 2024
Security, Health, Technology, Other Health, General Health, Pharmaceutical, Civil and political rights, AmerisourceBergen, Prescription, Law enforcement, Risk management

AmerisourceBergen Specialty Group, LLC (ABSG) is issuing notice to individuals who may have been impacted by a data security incident.

Key Points: 
  • AmerisourceBergen Specialty Group, LLC (ABSG) is issuing notice to individuals who may have been impacted by a data security incident.
  • ABSG’s parent company previously announced the data security incident, which is fully contained.
  • Through an investigation with the assistance of law enforcement, cybersecurity experts and outside lawyers, ABSG has now identified certain individuals whose personal information was involved in the incident.
  • ABSG is now issuing notification to impacted individuals via this media release and a substitute notice on its website.

The Lash Group Provides Substitute Notice of Data Incident to Affected Individuals

Retrieved on: 
Vendredi, mai 17, 2024
Technology, Pharmaceutical, Health, Security, Partnership, Patient, Eastern Time Zone, Prescription, Pharmacy, Law enforcement, AmerisourceBergen

The Lash Group, LLC is issuing a substitute notice to individuals who may have been impacted by a data security incident.

Key Points: 
  • The Lash Group, LLC is issuing a substitute notice to individuals who may have been impacted by a data security incident.
  • Lash Group’s parent company had previously announced a data security incident that has been fully contained.
  • In some instances, Lash Group does not have addresses for the individuals involved.
  • The Lash Group and its affiliates take this incident and the security of information entrusted to them very seriously.

Acclinate Raises $7M in Series A Funding to Accelerate Health Equity Revolution

Retrieved on: 
Mardi, mai 7, 2024
AmerisourceBergen, Labcorp, Entrepreneurship, Health, Enhanced, Clinical trial, Health equity, Partnership, Pharmaceutical industry

BIRMINGHAM, Ala., May 7, 2024 /PRNewswire/ -- Acclinate, a trailblazer in mobilizing diverse communities for enhanced health equity, today announced its $7 million Series A financing round.

Key Points: 
  • BIRMINGHAM, Ala., May 7, 2024 /PRNewswire/ -- Acclinate, a trailblazer in mobilizing diverse communities for enhanced health equity, today announced its $7 million Series A financing round.
  • Led by Cencora Ventures, with notable contributions from Labcorp and Latimer Ventures, the funding will enable Acclinate to scale its impact in the clinical trial diversity and health equity landscapes.
  • "This investment marks a significant milestone for Acclinate and underscores our commitment to revolutionizing health equity and clinical trial diversity at a larger scale," expressed Del Smith, CEO and Co-Founder of Acclinate.
  • This funding will help fuel Acclinate' s expansion and enhance its already powerful Enhanced Diversity in Clinical Trials (e-DICT) platform.

Whistleblower Law Collaborative Spring Update

Retrieved on: 
Mercredi, mai 1, 2024
AmerisourceBergen, CFTC, Boston Bar Association, WLC, Conference, FCA, McKesson Corporation, White collar, American Bar Association, DOJ, Multimedia, False Claims Act, Fraud, Pharmaceutical industry

BOSTON, May 1, 2024 /PRNewswire/ -- Whistleblower Law Collaborative LLC is now representing whistleblowers in emerging new practice areas including cryptocurrency fraud, anti-money laundering and sanctions evasion, and cybersecurity fraud .

Key Points: 
  • BOSTON, May 1, 2024 /PRNewswire/ -- Whistleblower Law Collaborative LLC is now representing whistleblowers in emerging new practice areas including cryptocurrency fraud, anti-money laundering and sanctions evasion, and cybersecurity fraud .
  • This spring marked Erica's fifth year teaching the popular Health Care Fraud & Abuse seminar at Boston University School of Law.
  • WLC has become one of the most recognized and successful whistleblower firms in the country.
  • Whistleblower Law Collaborative LLC , based in Boston, devotes its practice entirely to representing clients nationwide in bringing actions under the federal and state whistleblower laws and programs, False Claims Acts , and other whistleblower programs including those addressing financial fraud.

Parexel Announces CEO Succession Plan

Retrieved on: 
Lundi, mars 18, 2024
ChromeOS, Goldman Sachs, Ohio State University, Growth, AmerisourceBergen, Health care, Acquisition, Commercial, University, Luminary, EQT, Chairperson, Drug development, HBA, Health, Family, Tandem Diabetes Care, MHA, Pharmaceutical industry

Ms. Howell, who joined Parexel in 2018 as Chief Commercial and Strategy Officer, will be appointed to the company’s Board of Directors May 15.

Key Points: 
  • Ms. Howell, who joined Parexel in 2018 as Chief Commercial and Strategy Officer, will be appointed to the company’s Board of Directors May 15.
  • Mr. Macdonald will continue on the Board through Dec. 31, 2024, and will remain an industry advisor to EQT and the largest individual investor in Parexel.
  • Together, she and Jamie have worked to ensure Parexel is well positioned for the future.”
    “It’s been a privilege to lead Parexel during this critical period in the company’s strategic transformation,” said CEO Jamie Macdonald.
  • I’m truly grateful for my time with this amazing organization and to have been part of such an incredible team.”
    “I’m honored to serve as the next CEO of Parexel,” said Peyton Howell.

TEAMSTERS END STRIKE AT CENCORA/AMERISOURCEBERGEN, SECURE NEW CONTRACT ADDRESSING WORKERS' CONCERNS

Retrieved on: 
Jeudi, avril 4, 2024
Joint, International Brotherhood of Teamsters, AmerisourceBergen, Local, Morale, Drug

SACRAMENTO, Calif., April 3, 2024 /PRNewswire/ -- After nearly a month on the picket line, Teamsters Local 150 members have overwhelmingly ratified a three-year agreement, bringing an end to the strike at Cencora (formerly known as AmerisourceBergen). The new contract addresses workers' concerns over wages, health care, and paid time off.

Key Points: 
  • The new contract addresses workers' concerns over wages, health care, and paid time off.
  • "This was a hard fight, but everybody got something they wanted in the end.
  • Choy and his co-workers went on strike March 10 after months of contentious negotiations for a fair contract.
  • Founded in 1903, the International Brotherhood of Teamsters represents 1.3 million hardworking people in the U.S., Canada, and Puerto Rico.

TEAMSTERS AT CENCORA/AMERISOURCEBERGEN RALLY FOR FAIR CONTRACT IN SACRAMENTO

Retrieved on: 
Jeudi, mars 28, 2024
Local, Workplace, AmerisourceBergen, Strike, International Brotherhood of Teamsters, Management

SACRAMENTO, Calif., March 28, 2024 /PRNewswire/ -- Striking Teamsters at pharmaceutical giant Cencora (formerly known as AmerisourceBergen) rallied today outside the company's Sacramento distribution center. The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since March 11.

Key Points: 
  • The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since March 11.
  • Local 150 members went on strike after months of contentious negotiations for a contract that addresses years of concerns on the job.
  • The warehouse workers are seeking a fair wage progression, lower health care costs, stronger seniority rights, and paid time off.
  • "While Cencora executives rake in millions, hardworking Teamsters are left fighting for scraps," said Dale Wentz, Secretary-Treasurer of Local 150.

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

Retrieved on: 
Mercredi, février 14, 2024
AmerisourceBergen, EMA, Injection, Committee, Fiscal, CRL, Outlook, MAA, Ranibizumab, FDA, Calendar, Completion, Bevacizumab, Symantec Endpoint Protection, Chemistry, Therapy, CHMP, European Medicines Agency, AMD, Patient, SPA, Retina, CMC

ISELIN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced financial results for first quarter fiscal year 2024 and provided a corporate update.

Key Points: 
  • ISELIN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced financial results for first quarter fiscal year 2024 and provided a corporate update.
  • Importantly, the first subject was enrolled in NORSE EIGHT in January 2024,” commented Russell Trenary, President and Chief Executive Officer.
  • In January 2024, Outlook Therapeutics announced that it received written agreement on the NORSE EIGHT trial protocol from the FDA under a SPA for NORSE EIGHT.
  • Outlook Therapeutics expects NORSE EIGHT topline results and resubmission of the ONS-5010 BLA by the end of calendar year 2024.

Cencora Releases 2023 ESG Report

Retrieved on: 
Mercredi, février 7, 2024
Professional Services, Philanthropy, Pharmaceutical, Alternative Energy, Energy, DEI (Diversity, Equity and Inclusion), Health Insurance, Data Analytics, Foundation, Human Resources, Other Philanthropy, Health, Environmental, Social and Governance (ESG), Partnership, Team, AmerisourceBergen, Science Based Targets initiative, Administration, ESG, Social, Community, Yearbook, ERG, Patient, Workforce, Investment, Animal, EVP, CSA, Sustainability, DEI, Certification, Mental health, Targets, Index, Recycling, Science, Equity, Erg, Culture, Parental leave, Cancer, Pharmacist, Organization, Nursing

Cencora (formerly AmerisourceBergen), a global healthcare company, released its 2023 Environmental, Social and Governance (ESG) Report .

Key Points: 
  • Cencora (formerly AmerisourceBergen), a global healthcare company, released its 2023 Environmental, Social and Governance (ESG) Report .
  • The report and the related ESG Reporting Index feature detailed information on Cencora’s ESG performance and its commitment to operations that benefit the planet and people more broadly.
  • Cencora also released its 2023 Diversity, Equity and Inclusion (DEI) Progress Report , which outlines the company’s efforts to leverage benchmarks of availability for talent in the marketplace and enhance a culture of inclusion, bringing its teams under its new, united global brand, Cencora.
  • For more information on the 2023 ESG Report and DEI Progress Report, please visit: https://esg.cencora.com/reports